Soligenix Inc (SNGX) Actualités

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results PR Newswire PRINCETON...

Form EFFECT - Notice of Effectiveness

Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone

NEW YORK and PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical...

Form 8-K - Current report

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView is pleased to announce an exclusive Q&A...

Form 8-K - Current report

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma PR...

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor®...

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference PR Newswire PRINCETON...

Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news...